Orum Therapeutics, Inc.
KOE: 475830.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sung-Joo Lee
- Employees
- 20
- Headquarters
- Daejeon, South Korea
- IPO year
- 2025
- Market cap
- ₩1.7T
- Website
- https://www.orumrx.com
Loading 475830…
Loading profile data…Frequently asked questions about 475830
What does Orum Therapeutics, Inc. (475830.KQ) do?
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company focuses on degrader-antibody conjugate that combine antibody-drug conjugate with targeted protein degradation technology. Its lead product candidate is ORM-1153, a GSPT1 protein degrader tha...
Where does 475830.KQ trade?
Orum Therapeutics, Inc. (475830.KQ) trades on the KOSDAQ.
What sector is 475830.KQ in?
Orum Therapeutics, Inc. (475830.KQ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Orum Therapeutics, Inc.?
Sung-Joo Lee is the chief executive officer of Orum Therapeutics, Inc. (475830.KQ).
Where is Orum Therapeutics, Inc. headquartered?
Orum Therapeutics, Inc. is headquartered in South Korea.
Does 475830.KQ pay a dividend?
Orum Therapeutics, Inc. (475830.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 475830.KQ go public?
Orum Therapeutics, Inc. (475830.KQ) completed its initial public offering in 2025.